Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

133 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL. Capizzi RL. Semin Oncol. 1999 Apr;26(2 Suppl 7):3-21. Semin Oncol. 1999. PMID: 10348255 Review.
Cytoprotection in acute myelogenous leukemia (AML) therapy.
Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferbér A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N. Grosso D, et al. Semin Oncol. 2004 Dec;31(6 Suppl 18):67-73. doi: 10.1053/j.seminoncol.2004.12.016. Semin Oncol. 2004. PMID: 15726527 Clinical Trial.
Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.
Capizzi RL. Capizzi RL. Invest New Drugs. 1996;14(3):249-56. doi: 10.1007/BF00194527. Invest New Drugs. 1996. PMID: 8958179 Review.
WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells.
Alberts DS, Speicher LA, Krutzsch M, Wymer J, Capizzi RL, Conlon J, Barrett A, Aickin M. Alberts DS, et al. Among authors: capizzi rl. Eur J Cancer. 1996;32A Suppl 4:S17-20. doi: 10.1016/s0959-8049(96)00313-9. Eur J Cancer. 1996. PMID: 8976817
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD, Taylor CW, Lopez MH, Johnson CS, Capizzi RL. Paine GD, et al. Among authors: capizzi rl. Semin Oncol. 1996 Aug;23(4 Suppl 8):35-9. Semin Oncol. 1996. PMID: 8783664
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS, Capizzi RL. Taylor CW, et al. Among authors: capizzi rl. Eur J Cancer. 1997 Sep;33(10):1693-8. doi: 10.1016/s0959-8049(97)00221-9. Eur J Cancer. 1997. PMID: 9389935
Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL, Oster W. Capizzi RL, et al. Int J Hematol. 2000 Dec;72(4):425-35. Int J Hematol. 2000. PMID: 11197208 Review.
Clinical status and optimal use of amifostine.
Capizzi RL. Capizzi RL. Oncology (Williston Park). 1999 Jan;13(1):47-59; discussion 63, 67. Oncology (Williston Park). 1999. PMID: 10027198 Review.
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
Capizzi RL. Capizzi RL. Eur J Cancer. 1996;32A Suppl 4:S5-16. doi: 10.1016/s0959-8049(96)00333-4. Eur J Cancer. 1996. PMID: 8976816 Review.
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. List AF, et al. Among authors: capizzi rl. Semin Oncol. 1996 Aug;23(4 Suppl 8):58-63. Semin Oncol. 1996. PMID: 8783669
133 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page